FilingSEC EDGAR8-K
Precision BioSciences initiates dosing in Phase 1/2 trial for Duchenne muscular dystrophy therapy
· SEC accepted
StagePhase 1/2
Filing content
Precision BioSciences has dosed the first patient in its Phase 1/2 clinical trial for PBGENE-DMD, a gene-editing candidate for Duchenne muscular dystrophy. The company expects to report initial safety data by the end of 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…